Regeneron To Post Double-Digit Returns, Vetr Crowd Says

Shares of Regeneron Pharmaceuticals Inc REGN are down more than 19.5 percent year-to-date, but have recuperated almost 32 percent since their late-June lows. It seems like the Vetr crowd believes the rally will continue, as evidenced by its average price target of $481.40, which implies an upside potential of roughly 10.25 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Regeneron on Wednesday, from 3.0 Stars (Hold) to 4.0 Stars (Buy) - out of a possible 5.0 Stars rating.

It should be noted that, in accordance with the new rating, 76 percent of the crowd’s ratings are bullish.